NCT06506175尚未招募1 期
A Phase I Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- AUCtau
研究概览
简要总结
The study is being conducted to evaluate the effects of different dosage regimen on the pharmacokinetics of HRS9531 tablets in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Ability to understand the trial procedures, be able and willing to provide a written informed consent.
- •Male subject aged 18-55 years (both inclusive) at the time of signing informed consent.
- •Body weight ≥ 50.0 kg, body mass index (BMI) of 23.0-35.0 kg/m^2 (both inclusive) at screening.
- •Weight change does not exceed 5 kg within 3 months before screening.
- •Good general health as judged by the investigator, based on medical history, physical examination, vital signs, clinical laboratory and electrocardiogram (ECG).
排除标准
- •Known or suspected hypersensitivity to trial product(s) or related products.
- •With previous major organ diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, are judged by researchers to be unsuitable for the study.
- •Abnormal and clinically significant blood pressure at screening.
- •History of significant gastrointestinal diseases or related symptoms (e.g., nausea, vomiting, heartburn, or diarrhea), conditions affecting gastric emptying (e.g., pyloric stenosis), or previous gastrointestinal surgery (excluding polypectomy and appendectomy), or acute diarrhea or constipation within 7 days before randomization.
- •Blood donation within 1 month prior to screening, or blood donation ≥ 400 mL or blood loss ≥ 400 mL within 3 months prior to screening.
- •Presence of any clinically significant results in examination at screening visit.
- •Hepatitis B surface antigen (HBsAg), HIV antibody detection, treponema pallidum specific antibody detection, hepatitis C virus antibody (HCVAb) positive.
- •Presence of - clinically significant ECG results.
- •Known or suspected history of drug abuse or drug abuse, or urine drug screening test during the screening periodThose who are positive.
- •Addiction to tobacco and alcohol.
- •Individuals with special dietary habits deemed unsuitable for participation by the investigator, or those unable to adhere to the dietary requirements of the trial during the study period.
- •In the opinion of the investigator, there are any other conditions that interfere with the evaluation of the results of the trial or are not suitable for participation of this study.
结局指标
主要结局
AUCtau
时间窗: 0-24hrs after the 10th dosing
Area under the HRS9531 tablets concentration curve from time 0-24 hours after the 10th dosing
次要结局
- Tmax(First dose at day 1 and post-dose at day 10)
- Cmax(First dose at day 1 and post-dose at day 10)
- Incidence and severity of adverse events(Screening period up to Day 45)
- t1/2(First dose at day 1 and post-dose at day 10)
- Anti-HRS9531 antibody(Before First dose at day 1 to Day 45)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Felzartamab in Healthy Adult SubjectsHealthyNCT06285201TJ Biopharma Co., Ltd.60
已完成
1 期
Pharmacokinetic Characteristics and Safety After Administration of NVP-2002HealthyNCT04961905NVP Healthcare96
已完成
1 期
Fentanyl Sublingual Spray in Opioid Naive ParticipantsPharmacologyNCT02641340INSYS Therapeutics Inc96
Unknown
1 期
A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy SubjectsHealthyNCT04587011HK inno.N Corporation40
已完成
1 期
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic PatientsDyslipidemiasFamilial HypercholesterolemiaHypertriglyceridemiaNCT03747224Arrowhead Pharmaceuticals93